Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.49 +0.27 (+1.03%)
Official Closing Price Updated: 7:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Got $200? 2 Dividend Stocks to Buy and Hold Forever
These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock. 
Via The Motley Fool
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
Pfizer CEO highlights savings, leadership changes, and acquisition-driven growth amid significant revenue loss challenges projected by 2026-2028. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts and biotech recovery delays. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Is Pfizer Stock Undervalued at Current Prices?
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy in 2025
Via The Motley Fool
Investing $5,000 Just Once in These 3 Ultra-High-Yielding Stocks Could Earn You $320 in Passive Income Every Year
Via The Motley Fool
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts are expected by 2025. 
Via Benzinga
Pfizer Reveals Encouraging Data From Pivotal Bladder Cancer Trial
Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer. 
Via Benzinga
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Should You Buy Pfizer Stock Right Now in 2025?
Via The Motley Fool
Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns
Explore established industry leaders with impressive dividend yields that are demonstrating the potential for growth and continued performance in 2025. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
From Pfizer Inc.
Via Business Wire
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind. 
Via Benzinga
Topics ETFs
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk. Study estimates 7-9 excess GBS cases per million doses. 
Via Benzinga
Exposures Product Safety
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Via The Motley Fool
Investing $50,000 in Each of These 5 Stocks Could Make You Nearly $17,500 in Passive Income in 2025
Via The Motley Fool
Warren Buffett's Warning to Wall Street Reached Deafening Proportions in 2024. Here's What to Do as 2025 Gets Started.
Via The Motley Fool
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Pfizer Antiviral Paxlovid's Extended Use Shows Mixed Results for Long COVID Relief: Study
A patient-led study examines the potential of extended Paxlovid courses for Long COVID relief, documenting varied outcomes and emphasizing the need for clinical trials. 
Via Benzinga
Exposures COVID-19
25 Top Dividend Stocks to Buy and Hold in 2025
Via The Motley Fool
Time to Dump or Double Up on SCHD?
SCHD shares have fallen nearly 10% in a month. 
Via The Motley Fool
AskSlim Market Week - Friday, Jan. 3
An analysis and commentary on the financial markets. 
Via Talk Markets
Topics Futures Stocks / Equities
3 Ultra-High-Yield Dividend Stocks That Are Screaming Buys in 2025
Three high-octane income stocks -- sporting an average yield of 7.93% -- can fatten investors' pocketbooks in the new year. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.